Inhaler corticosteroid device market to reach $23.18 billion by 2030

The inhaler corticosteroid device market is projected to grow from $16.83 billion in 2025 to $23.18 billion by 2030, driven by rising respiratory disease cases, smart-device adoption and telehealth expansion. North America leads now, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Inhaler corticosteroid devices treat chronic respiratory conditions by delivering anti-inflammatory medicine directly to the lungs. - The devices help manage asthma and COPD symptoms while reducing side effects tied to oral corticosteroids. - Rising respiratory disease burden is increasing demand for targeted inhaler therapy worldwide.

What happened: - The Business Research Company released its Inhaler Corticosteroid Device Market Report 2026, covering market size, trends and a global forecast for 2026-2035. - The market is projected to grow from $16.83 billion in 2025 to $17.98 billion in 2026, a 6.8% CAGR. - The report forecasts the market will reach $23.18 billion by 2030, growing at a 6.6% CAGR during the forecast period. - North America was the largest market in 2025. - Asia-Pacific is expected to be the fastest-growing region in the coming years.

The details: - Historical growth has been supported by rising asthma and COPD cases, stronger awareness of inhaler therapies and government efforts to improve respiratory health. - Metered-dose inhaler innovation and growth in hospital and home care services also supported recent expansion. - Future growth is expected to come from AI and IoT integration, eco-friendly inhalers, telehealth expansion and personalized medication delivery. - Key trends highlighted in the report include smart inhaler integration, personalized dosage management, telehealth-enabled patient monitoring, sustainable device design and improved aerosol delivery. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The June 2025 data cited in the report showed 854,922 emergency hospital admissions for respiratory diseases in England in the financial year ending 2024. - That figure equaled 1,428 admissions per 100,000 people and was 7% higher than the previous year. - The report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, updated graphics and future-trend analysis. - The report also points readers to a free sample and the full report: Download a free sample and View the full report.

Between the lines: - The growth story points to a mix of clinical need and technology upgrade cycles. - Smart devices and telehealth suggest the market is moving beyond basic drug delivery toward monitoring and adherence tracking. - The regional outlook suggests mature healthcare systems are driving current volume, while emerging markets may carry the next wave of growth. - The England admission data underscores how worsening respiratory disease rates can translate into higher demand for inhaled therapies.

What's next: - The market’s next phase will likely center on connected inhalers, better dosing precision and more sustainable device designs. - Asia-Pacific growth may narrow the gap with North America if demand and access continue to expand. - Broader respiratory disease prevalence and telehealth adoption are likely to keep supporting device demand through 2030.

The bottom line: - Inhaler corticosteroid devices are shifting from a mature treatment category to a tech-enabled respiratory care market with steady global growth ahead.